|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Apoptosis and cancer chemotherapy显示文摘 | EL Arriola and JA Hickman | 1996 | Behring Inst Mirt1996，97，： | 1 |
| 2 | Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase显示文摘 | Chapman RS Whetton AD Chresta CM | 1995 | Mol Pharm1995，48，： | 1 |
| 3 | AZD8055 is a potent,selective,and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，1： | 1 |
| 4 | Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bxl - 2 ratio 显示文摘 | Chresta CM Masters JR Hickman JA | 1996 | Cancer Res1996，66，8： | 1 |
| 5 | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | CHRESTA CM DAVIES BR HICKSON I | 2010 | Cancer Res2010，70，1： | 1 |
| 6 | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity 显示文摘 | CHRESTA CM DAVIES BR HICKSON I | 2010 | Cancer Res2010，70，1： | 1 |
| 7 | AZD8055 is a potent,selective,and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | | 0，，01： | 1 |
| 8 | Apoptosis and cancer chemotherapy显示文摘 | Chresta CM Arriola EL Hickman JA | 1996 | Behring Inst Mitt1996，，97： | 1 |
| 9 | Simultaneous inhibition of mTOR-C 1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells显示文摘 | Sini P James D Chresta C | | 0，，04： | 1 |
| 10 | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，： | 1 |
| 11 | Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition显示文摘 | Paul Roepman Andreas Schlicker Josep Tabernero Ian Majewski Sun Tian Victor Moreno Mireille H Snel Christine M Chresta Robert Rosenberg Ulrich Nitsche Teresa Macarulla Gabriel Capella Ramon Salazar George Orphanides Lodewyk FA Wessels Rene Bernards Iris M | 2013 | Int. J. Cancer2013，，3： | 1 |
| 12 | Hypersensitivity of human testicular tumours to etoposide induced apoptosis is associated with functional p53 and a high Bax: Bcl-2ratio显示文摘 | Chresta CM Masters JR Hickman JA | 1996 | Cancer Res1996，56，： | 1 |
| 13 | AZD8055 is a potent, selective, and orally bioavailable ATP-competi- tive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，1： | 1 |
| 14 | AZD8055 is a potent,selective,and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，1： | 1 |
| 15 | Hypersensitivity of human teticular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio显示文摘 | Chresta C M Masters J R W Hickman J A | 1996 | Cancer Res1996，56，8： | 1 |
| 16 | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，1： | 1 |
| 17 | Relationship between topoisomerase Ⅱ level andchemosensitivity in human tumor cell lines显示文摘 | Fry AM Chresta CM Davies SM | 1991 | Cancer Res1991，51，： | 1 |
| 18 | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian tar- get of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity 显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer Res2010，70，1： | 1 |
| 19 | AZD8055 is a potent, selective,and orally bioavailable ATP-competitive mammalian tar- get of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity显示文摘 | Chresta CM Davies BR Hickson I | 2010 | Cancer research2010，70，1： | 1 |
| 20 | Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition显示文摘 | Paul Roepman Andreas Schlicker Josep Tabernero Ian Majewski Sun Tian Victor Moreno Mireille H Snel Christine M Chresta Robert Rosenberg Ulrich Nitsche Teresa Macarulla Gabriel Capella Ramon Salazar George Orphanides Lodewyk FA Wessels Rene Bernards Iris M | 2013 | Int J Cancer2013，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员